EUCTR2016-004448-12-IT进行中（未招募）1 期
A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma - ARQ 087 in subjects with FGFR2 gene fusion in inoperable or advanced intrahepatic cholangiocarcinoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ARQULE INC
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Tissue samples for genetic testing will be obtained from subjects who meet the following pre-screening eligibility criteria:
- •1.Signed written informed consent to permit tissue analysis
- •2.18 years of age or older
- •3.No medical history that is excluded per the study treatment eligibility criteria
- •4.Eastern Cooperative Oncology Group (ECOG) performance status = 1 (Appendix 2 of the protocol)
- •5.Eligible for or receiving systemic therapy for inoperable or advanced iCCA
- •6.Not currently eligible for curative local or surgical therapy
- •To be enrolled in the study, once the FGFR2 gene fusion status is determined, each prospective subject must meet all of the following inclusion criteria:
- •1.Signed written informed consent granted prior to initiation of any study-specific procedures
- •2.18 years of age or older
- •3.Histologically or cytologically confirmed locally advanced, inoperable (where surgery is not indicated due to disease extension, co-morbidities, or other technical reasons), or metastatic iCCA or mixed histology tumors (combined hepatocellular-cholangiocarcinoma [cHCC-CCA])
- •4.FGFR2 gene fusion status confirmed by NGS or FISH testing
- •-Test positive by FISH by the central laboratory designated by the Sponsor
- •-Have FGFR2 gene fusion documented by a local or central laboratory using standard protocols and approved by local IRB/IEC, Clinical Laboratory Improvement Amendments (CLIA), or other similar agency. If the FGFR2 gene fusion is identified by a laboratory other than the Sponsor’s central laboratory, then archival and/or recent tissue biopsy samples or a tissue block suitable for genetic testing must be available for confirmatory testing by FISH by the Sponsor’s central laboratory (Refer to Section 6.7 and the Laboratory Manual for tissue preparation requirements). If a subject has documentation from a local or central laboratory indicating that they test negative for FGFR2 gene fusion, that subject may not be enrolled in the study.
- •5.Received at least one regimen of prior systemic therapy and then experienced documented radiographic progression or was not able to tolerate prior systemic therapy.
- •-if the subject received at least 4 cycles of systemic therapy and no measurable tumor reduction compared to the previous scan is observed, such subject can be enrolled
- •-if the subject received immunotherapy, the documented radiographic disease progression is required
- •-if the subject experienced disease progression within 6 months of adjuvant therapy, such therapy should be considered as the line of treatment rather than adjuvant therapy
- •6.Measurable disease by RECIST version 1.1 criteria
- •7.ECOG performance status = 1 (Appendix 2)
- •8.Adequate organ functions as indicated by the following laboratory values (based on screening visit values from the central laboratory).
- •-Hematological
- •?Hemoglobin (Hgb) = 9.0 g/dL
- •?Absolute neutrophil count (ANC) = 1.5 x 10*9/L
- •?Platelet count = 75 x 10*9/L
- •?International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or = 3 for subjects receiving anticoagulant therapy such as Coumadin or heparin
- •?Total bilirubin = 2 x ULN
- •?Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 ULN (= 5 x ULN for subjects with liver metastases)
- •?Albumin = 2.8 g/dL
- •?Serum creatinine = 1.5 x ULN
- •?Creatinine clearance of = 60 mL/min as estimated by the Cockcroft-Gault equation
- •9.Male or female subjects of child-producing potential must agree to use double
排除标准
- •1.Systemic anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ARQ 087
- •2.Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of ARQ 087
- •3.Previous treatment with any FGFR inhibitor (e.g., ponatinib, dovitinib, nintedanib, AZD4547, NVP-BGJ398, LY2784455, BAY1163877)
- •-Subjects who received less than four weeks of therapy and were unable to continue therapy due to toxicity will be allowed to participate
- •4.Unable or unwilling to swallow the complete daily dose of ARQ 087 capsules
- •5.Clinically unstable central nervous system (CNS) metastases (to be eligible, subjects must have stable disease = 3 months, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and/or have CNS metastases well controlled by low-dose steroids, anti-epileptics, or other symptom-relieving medications)
- •6.Current evidence of corneal or retinal disorder, including but not limited to bullous/band keratopathy, keratoconjunctivitis, corneal abrasion, inflammation/ulceration, confirmed by ophthalmologic examination
- •7.Concurrent uncontrolled or active hepatobiliary disorders, untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, biloma or abscess (to be eligible, the subjects have to be treated and disorders/complications should be resolved within 2 weeks prior to the first dose of ARQ 087)
- •8.History of significant cardiac disorders:
- •-Myocardial infarction (MI) or congestive heart failure defined as Class II to IV per the New York Heart Association (NYHA) classification within 6 months of the first dose of ARQ 087 (MI that occurred > 6 months prior to the first dose of ARQ 087 will be permitted)
- •-QTcF > 500 msec (males or females)
- •9.Significant gastrointestinal disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 087 (e.g., Crohn’s disease, ulcerative colitis, extensive gastric resection)
- •10.Previous malignancy within 2 years of the first dose of ARQ 087, except curatively treated or low grade malignancies such as non-melanoma skin cancer, carcinoma in-situ of the breast, cervix, and superficial bladder tumors
- •11.Concurrent uncontrolled illness not related to cancer, including but not limited to:
- •-Psychiatric illness/substance abuse/social situation that would limit compliance with study requirements
- •-Known uncontrolled human immunodeficiency virus (HIV) infection
- •12.Blood or albumin transfusion within 5 days of the blood draw being used to confirm eligibility
- •13.Pregnant or breast feeding
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors with FGFR Genetic AlterationsAdvanced Solid Tumors with FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma with FGFR2 Gene FusionMedDRA version: 20.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10073077Term: Intrahepatic cholangiocarcinomaSystem Organ Class: 100000004864EUCTR2015-001443-36-ITARQULE INC120
进行中（未招募）
1 期
Study of patients with an increase in the size of certain parts of their body and circulatory abnormalities.subjects (at least 6 years) suffering from diseases overgrowth and vascular anomalies with genetic alterations of the PI3K / AKT pathway.MedDRA version: 20.0 Level: SOC Classification code 10010331 Term: Congenital, familial and genetic disorders System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-000558-37-ITArQule, Inc.16
进行中（未招募）
不适用
A Randomized Phase 2 Study of ARQ 197 versus Investigator’s Choice of Second-Line Chemotherapy in Patients with Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment with One Prior Chemotherapy RegimeEUCTR2007-004622-25-LVArQule Inc.338
进行中（未招募）
不适用
A Randomized Phase 2 Study of ARQ 197 versus Gemcitabine in Treatment-naïve Patients with Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinomanresectable Locally Advanced or Metastatic Pancreatic AdenocarcinomaMedDRA version: 9.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticEUCTR2007-002727-32-LVArQule Inc.72
进行中（未招募）
不适用
A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Associated TumorsEUCTR2009-011669-10-GBArQule, Inc.39